Press Releases Year None2022202120202019201820172016 Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 June 1, 2022 PDF Version View HTML Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference May 17, 2022 PDF Version View HTML Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update May 10, 2022 PDF Version View HTML Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022 May 5, 2022 PDF Version View HTML Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast May 3, 2022 PDF Version View HTML Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings April 27, 2022 PDF Version View HTML Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201 April 26, 2022 PDF Version View HTML Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings April 25, 2022 PDF Version View HTML Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings April 25, 2022 PDF Version View HTML Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference April 7, 2022 PDF Version View HTML Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last » Displaying 11 - 20 of 28
